Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.54), $0.05 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $126.05 million versus the consensus estimate of $124.25 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.